Share This Article:

Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2

Full-Text HTML XML Download Download as PDF (Size:337KB) PP. 433-443
DOI: 10.4236/pp.2014.54053    3,255 Downloads   4,070 Views  

ABSTRACT

The purpose of this study was to analyze the effects of the treatment with Exenatide joint to insulin detemir. The study was carried out with obese patients with type 2 diabetes mellitus (DM2) and deficient control, despite intensive insulin therapy combined with oral antidiabetics. A longitudinal study was made with 15 patients controlled by the Endocrinology and Nutrition Section of the Reina Sofía University Hospital, Murcia. These patients were treated with Exenatide joint to insulin during 3, 6 and 12 months. Statistically meaningful differences (p < 0.05) were observed in the reduction of HbA1c in the 3 and 6 months treatment groups (initial HbA1c: 9.55% ± 1.086%, weight: 119.94 kg, insulin requirement: 0.71 IU/kg/day; after 3 months: HbA1c: 7.77% ± 1.164%, weight: 98.13 kg, insulin requirement: 0.59 IU/kg/day; after 6 months: HbA1c: 7.21%, weight: 97.93 kg, insulin requirement: 0.55 IU/kg/day). It was observed that the association of Exenatide and insulin promotes an improvement in several indicators such as weight, body mass index (BMI), systolic pressure (SP), diastolic pressure (DP), triglycerides (TG), cLDL, cHDL and total cholesterol (TC), in patients with diabetes resistant to conventional therapy. However, these improvements were statistically no significant (p < 0.05). It is possible to talk of a reduction of cardiovascular risk factors in patients with Exenatide, being thus a suitable option for this kind of individuals. It is important to emphasize the fact that our study showed bigger body-weight reductions results after 6 and 12 months, as compared to the researches quoted.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

López Ruiz, A. , Núñez Sánchez, M. , García-Talavera Espín, N. , Avilés, A. , Peso Gilsanz, C. , Sánchez, R. , Gallego García, M. , Palao, J. , Ortuño, M. , Navarro, S. and Obesity Unit of the Hospital Reina Sofía, C. (2014) Optimization of Exenatide plus Detemir Treatment for Morbid Obese Patients with Insulin Dependent Diabetes Resistant to Conventional Treatment. Effect of Exenatide on Patients with Mellitus Diabetes Type 2. Pharmacology & Pharmacy, 5, 433-443. doi: 10.4236/pp.2014.54053.

References

[1] National Health Service (NHS) (2007) Exenatide. New Drug Evaluation, 84.
[2] Centro Andaluz de Información de Medicamentos (CADIME) (2009) Exenatida (DCI). Ficha de Novedad Terapéutica 2.
[3] Campoamor, F. (2008) Exenatida en la diabetes mellitus tipo 2. Comisión de Evaluación de Medicamentos, Islas Baleares.
[4] Verzegnassi, F. and Chinello, M. (2010) Exenatide in Type 2 Diabetes. Lancet, 376, 1052-1053.
http://dx.doi.org/10.1016/S0140-6736(10)61485-7
[5] Peters, A. (2010) Incretin-Based Therapies: Review of Current Clinical Trial Data. American Journal of Medicine, 123, S28-S37. http://dx.doi.org/10.1016/j.amjmed.2009.12.007
[6] Wajcberg, E. and Tavaria, A. (2009) Exenatide: Clinical Aspects of the First Incretin-Mimetic for the Treatment of Type 2 Diabetes Mellitus. Expert Opinion on Pharmacotherapy, 10, 135-142.
http://dx.doi.org/10.1517/14656560802611832
[7] Segal, J.B., Dy, S.M., Millman, E.A., Herbert, R., Bass, E.B. and Wu, A. (2007) Diffusion into Use of Exenatide for Glucose Control in Diabetes Mellitus: A Retrospective Cohort Study of a New Therapy. Clinical Therapeutics, 29, 1784-1794. http://dx.doi.org/10.1016/j.clinthera.2007.08.021
[8] Philippe, J. (2009) Role and Indication of GLP-1 Analogues in the Treatment of Type 2 Diabetes. Revue Médicale Suisse, 5, 1260-1262, 1264-1265.
[9] Reuter, H. and Erdmann, E. (2007) Exenatide—An Incretin-Mimetic Agent for the Treatment of Type 2 Diabetes Mellitus. Deutsche Medizinische Wochenschrift, 132, 571-574. http://dx.doi.org/10.1055/s-2007-970380
[10] Gill, A., Hoogwerf, B.J., Burger, J., Bruce, S., Macconell, L., Yan, P., et al. (2010) Effect of Exenatide on Heart Rate and Blood Pressure in Subjects with Type 2 Diabetes Mellitus: A Double-Blind, Placebo-Controlled, Randomized Pilot Study. Cardiovascular Diabetology, 9, 6.
http://dx.doi.org/10.1186/1475-2840-9-6
[11] Moretto, T.J., Milton, D.R., Ridge, T.D., Macconell, L.A., Okerson, T., Wolka, A.M., et al. (2008) Efficacy and Tolerability of Exenatidemonotherapy over 24 Weeks in Antidiabetic Drug-Naive Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Clinical Therapeutics, 30, 1448-1460.
http://dx.doi.org/10.1016/j.clinthera.2008.08.006
[12] Klonoff, D.C., Buse, J.B., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., et al. (2008) Exenatide Effects on Diabetes, Obesity, Cardiovascular Risk Factors and Hepatic Biomarkers in Patients with Type 2 Diabetes Treated for at Least 3 Years. Current Medical Research and Opinion, 24, 275-286.
[13] Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M., Zhuang, D., DURATION-1 Study Group, et al. (2008) Exenatide Once Weekly versus Twice Daily for the Treatment of Type 2 Diabetes: A Randomised, Open-Label, Non-Inferiority Study. Lancet, 372, 1240-1250.
http://dx.doi.org/10.1016/S0140-6736(08)61206-4
[14] Okerson, T., Yan, P., Stonehouse, A., Brodows, R. and Bhole, D. (2008) Exenatide Improved Systolic Blood Pressure Compared to Insulin or Placebo in Patients with Type 2 Diabetes. Diabetologia, 51, S350.
[15] Bergenstal, R., Kim, T., Yan, P., Darsow, T., Walsh, B., Okerson, T., et al. (2009) Exenatide Once Weekly Improved Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes during One Year of Treatment. Diabetes, 58, A43.
[16] Bhushan, R., Elkind-Hirsch, K.E., Bhushan, M., Butler, W.J., Duncan, K. and Marrioneaux, O. (2009) Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting. Diabetes Technology & Therapeutics, 11, 353-359.
http://dx.doi.org/10.1089/dia.2008.0090
[17] Kothare, P.A., Linnebjerg, H., Isaka, Y., Uenaka, K., Yamamura, A., Yeo, K.P., de la Peña, A., Teng, C.H., Mace, K., Fineman, M., Shigeta, H., Sakata, Y. and Irie, S. (2008) Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients with Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 48, 1389-1399.
http://dx.doi.org/10.1177/0091270008323750
[18] Linnebjerg, H., Kothare, P., Park, S., Mace, K. and Mitchell, M. (2009) The Effect of Exenatide on Lisinopril Pharmacodynamics and Pharmacokinetics in Patients with Hypertension. International Journal of Clinical Pharmacology and Therapeutics, 47, 651-658. http://dx.doi.org/10.5414/CPP47651
[19] Menéndez Torre, E., Lafita Tejedor, J., Artola Menéndez, S., Millán Núñez-Cortés, J., Alonso García, á., Puig Domingo, M., García Solans, J.R., álvarez Guisasola, F., García Alegría, J., Mediavilla Bravo, J., Fernández-Santos, C.M. and Romero González, R. (2010) Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2. Avances en Diabetología, 26, 331-338. http://dx.doi.org/10.1016/S1134-3230(10)65006-5
[20] Svec, F. (2010) Incretin Physiology and Its Role in Type 2 Diabetes Mellitus. Journal of the American Osteopathic Association, 110, eS20-eS24.
[21] Sudhakaran, C., Fathima, M., Anjana, R.M., Unnikrishnan, R.I. and Mohan, V. (2010) Effectiveness of Exenatide in Asian Indians in a Clinical Care Setting. Diabetes Technology & Therapeutics, 12, 613-618.
http://dx.doi.org/10.1089/dia.2010.0033
[22] Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K. and Trautmann, M. (2010) Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial. Lancet, 375, 2234-2243.
http://dx.doi.org/10.1016/S0140-6736(10)60406-0
[23] Bergenstal, R.M., Wysham, C., Macconell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., Porter, L.E. and DURATION-2 Study Group (2010) Efficacy and Safety of Exenatide Once Weekly versus Sitagliptin or Pioglitazone as an Adjunct to Metformin for Treatment of Type 2 Diabetes (DURATION-2): A Randomised Trial. Lancet, 376, 431-439. http://dx.doi.org/10.1016/S0140-6736(10)60590-9
[24] Blevins, T., Han, J., Nicewarner, D., Chen, S., Oliveira, J.H. and Aronoff, S. (2010) Exenatide Is Non-Inferior to Insulin in Reducing HbA1c: An Integrated Analysis of 1423 Patients with Type 2 Diabetes. Postgraduate Medicine, 122, 118-128. http://dx.doi.org/10.3810/pgm.2010.05.2149
[25] Natarajan, B., Edavalath, M., Davies, J., Jenkins, L., Marshall-Richards, N., Evans, D., Price, D.E. and Stephens, J.W. (2010) Clinical Experience with Exenatide in a Routine Secondary Care Diabetes Clinic. Primary Care Diabetes, 4, 57-60. http://dx.doi.org/10.1016/j.pcd.2009.11.001
[26] Yoon, N.M., Cavaghan, M.K., Brunelle, R.L. and Roach, P. (2009) Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice over Two Years in an Academic Endocrinology Outpatient Setting. Clinical Therapeutics, 31, 1511-1523. http://dx.doi.org/10.1016/j.clinthera.2009.07.021
[27] Drucker, D.J., Buse, J.B., Taylor, K., Kendall, D.M., Trautmann, M., Zhuang, D., Porter, L. and DURATION-1 Study Group (2008) Exenatide Once Weekly versus Twice Daily for the Treatment of Type 2 Diabetes: A Randomised, Open-Label, Non-Inferiority Study. Lancet, 372, 1240-1250. http://dx.doi.org/10.1016/S0140-6736(08)61206-4
[28] Forti, A., Garcia, E.G., Yu, M.B., Jimenez, M.C., Brodows, R.G. and Oliveira, J.H. (2008) Efficacy and Safety of Exenatide Administered before the Two Largest Daily Meals of Latin American Patients with Type 2 Diabetes. Current Medical Research and Opinion, 24, 2437-2447.
http://dx.doi.org/10.1185/03007990802282398
[29] Nyström, T., Gutniak, M.K., Zhang, Q., Zhang, F., Holst, J.J., Ahrén, B. and Sjöholm, Å. (2004) Effects of Glucagon-Like Peptide-1 on Endothelial Function in Type 2 Diabetes Patients with Stable Coronary Artery Disease. American Journal of Physiology-Endocrinology and Metabolism, 287, E1209-E1215.
http://dx.doi.org/10.1152/ajpendo.00237.2004
[30] Thrainsdottir, I., Malmberg, K., Olsson, A., Gutniak, M. and Rydén, L. (2004) Initial Experience with GLP-1 Treatment on Metabolic Control and Myocardial Function in Patients with Type 2 Diabetes Mellitus and Heart Failure. Diabetes and Vascular Disease Research, 1, 40-43.
http://dx.doi.org/10.3132/dvdr.2004.005
[31] Sokos, G.G., Nikolaidis, L.A., Mankad, S., Elahi, D. and Shannon, R.P. (2006) Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients with Chronic Heart Failure. Journal of Cardiac Failure, 12, 694-699.
http://dx.doi.org/10.1016/j.cardfail.2006.08.211
[32] Bunck, M.C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R.M., Heine, R.J., et al. (2010) Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition. Diabetes Care, 33, 1734-1737. http://dx.doi.org/10.2337/dc09-2361
[33] Buse, J.B., Bergenstal, R.M., Glass, L.C., Heilmann, C.R., Lewis, M.S., Kwan, A.Y., Hoogwerf, B.J. and Rosenstock, J. (2010) Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients with Type 2 Diabetes: A Randomized, Controlled Trial. Annals of Internal Medicine, 154, 1-12.
[34] Kolterman, O.G., Buse, J.B., Fineman, M.S., Gaines, E., Heintz, S., Bicsak, T.A., Taylor, K., Kim, D., Aisporna, M., Wang, Y. and Baron, A.D. (2003) Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism, 88, 3082-3089.
http://dx.doi.org/10.1210/jc.2002-021545
[35] Arnolds, S., Dellweg, S., Clair, J., Dain, M.P., Nauck, M.A., Rave, K. and Kapitza, C. (2010) Further Improvement in Postprandial Glucose Control with Addition of Exenatide or Sitagliptin to Combination Therapy with Insulin Glargine and Metformin: A Proof-of-Concept Study. Diabetes Care, 33, 1509-1515. http://dx.doi.org/10.2337/dc09-2191
[36] Yoon, N.M., Cavaghan, M.K., Brunelle, R.L. and Roach, P. (2009) Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice over Two Years in an Academic Endocrinology Outpatient Setting. Clinical Therapeutics, 31, 1511-1523. http://dx.doi.org/10.1016/j.clinthera.2009.07.021
[37] Sheffield, C.A., Kane, M.P., Busch, R.S., Bakst, G., Abelseth, J.M. and Hamilton, R.A. (2008) Safety and Efficacy of Exenatide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus. Endocrine Practice, 14, 285-292.
http://dx.doi.org/10.4158/EP.14.3.285
[38] Nayak, U.A., Govindan, J., Baskar, V., Kalupahana, D. and Singh, B.M. (2010) Exenatide Therapy in Insulin-Treated Type 2 Diabetes and Obesity. QJM, 103, 687-694.
http://dx.doi.org/10.1093/qjmed/hcq112
[39] Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., et al. (2006) Management of Hyperglycaemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29, 1963-1972.
http://dx.doi.org/10.2337/dc06-9912
[40] Schernthaner, G., Barnett, A.H., Betteridge, D.J., Carmena, R., Ceriello, A., Charbonnel, B., et al. (2010) Is the ADA/EASD Algorithm for the Management of Type 2 Diabetes (January 2009) Based on Evidence or Opinion? A Critical Analysis. Diabetologia, 53, 1258-1269.
http://dx.doi.org/10.1007/s00125-010-1702-3
[41] German Diabetes Association, Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H.U., et al. (2009) Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus: Update of the Evidence-Based Guideline of the German Diabetes Association. Experimental and Clinical Endocrinology & Diabetes, 117, 522-557.
http://dx.doi.org/10.1055/s-0029-1239559
[42] Apovian, C.M., Bergenstal, R.M., Cuddihy, R.M., Qu, Y., Lenox, S., Lewis, M.S., et al. (2010) Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes. American Journal of Medicine, 123, 468.e9-17.
[43] Robles, G.I. and Singh-Franco, D. (2009) A Review of Exenatide as Adjunctive Therapy in Patients with Type 2 Diabetes. Drug Design, Development and Therapy, 3, 219-240.
http://dx.doi.org/10.2147/DDDT.S3321

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.